FY results as expected.26 Feb 2026 11:05
An interesting update, though not a bullish one. Interesting that work was sub contracted out when Pitreavie was shut down.
Packaging 5% adj operating profit (this includes Pitreavie), Manufacturing 10% adj operating profit.
Packaging sounds to be the problem "..profits were significantly below 2024 as the business experienced weaker-than-expected demand, delays in new business...". Manufacturing sounds the better part, "excluding Pitreavie, performed well. "
"We expected Pitreavie to be a significant contributor to the Group in 2025, but its performance was well below expectations, mainly due to the impact of the tragic incident.." I think we can infer that the acquisition may have been sub optimal, now that further investment is required "£1.2m investment in new equipment will return the business to full operational capacity in Q2 2026". I cant help feeling that due diligence was poor on this acquisition. Though they do have a long record of other acquisitions.
So its currently trough earnings, against poor macro, with a slightly blotted copy book IMO. Lets hope things can improve through 2026. The lack of financial guidance, and wildly fluctuating earnings does make it hard to put on a multiple on this right now. The yield is currently 5% if we assume no dividend growth, the Buy back really isnt making a material difference here, with a hand full of purchases per month. Aberforth recently increased +1% to 12%, which tells you there is deep value on offer here, even if their might be a long wait before it is realised. Its a hold for me.
I thought the pension scheme may have progressed further than a "possible buy-in". Seems most things at Macfarlane are fairly slow to progress.
The Board proposes to maintain the final dividend at 2.70 pence per share, amounting to a full-year dividend of 3.66 pence per share paid on Friday 12 June 2026 to those shareholders on the register on Friday 15 May 2026 (ex-dividend date 14 May 2026).
Using a share price of 71p, that is 3.8% return. (if you overlook the 12 month 34% decline in share price).